Cargando…

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria

BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC(50) values indicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Okomo-Adhiambo, Margaret, Nguyen, Ha T, Abd Elal, Anwar, Sleeman, Katrina, Fry, Alicia M, Gubareva, Larisa V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186475/
https://www.ncbi.nlm.nih.gov/pubmed/24299049
http://dx.doi.org/10.1111/irv.12215
_version_ 1782338069447311360
author Okomo-Adhiambo, Margaret
Nguyen, Ha T
Abd Elal, Anwar
Sleeman, Katrina
Fry, Alicia M
Gubareva, Larisa V
author_facet Okomo-Adhiambo, Margaret
Nguyen, Ha T
Abd Elal, Anwar
Sleeman, Katrina
Fry, Alicia M
Gubareva, Larisa V
author_sort Okomo-Adhiambo, Margaret
collection PubMed
description BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC(50) values indicative of clinically relevant resistance and insufficient harmonization of NI testing methodologies among surveillance laboratories. In 2012, the WHO working group on influenza antiviral susceptibility (WHO-AVWG) developed criteria to facilitate consistent interpretation and reporting of NI assay data. METHODS: The WHO-AVWG classification criteria were applied in interpreting NI assay data for two FDA-licensed NAIs, oseltamivir and zanamivir, for viruses collected in the United States during the 2011–2012 winter season. RESULTS: All A (H1N1)pdm09 viruses (n = 449) exhibited normal inhibition by oseltamivir and zanamivir, with the exception of eight viruses (1·8%) with highly reduced inhibition by oseltamivir, which carried the H275Y marker of oseltamivir resistance. A (H3N2) viruses (n = 978) exhibited normal inhibition by both NAIs, except for one virus with highly reduced inhibition by zanamivir due to the cell culture-selected NA change, Q136K. Type B viruses (n = 343) exhibited normal inhibition by both drugs, except for an isolate with reduced inhibition by both NAIs that had the cell culture-selected A200T substitution. CONCLUSIONS: WHO-AVWG classification criteria allowed the detection of viruses carrying the established oseltamivir resistance marker, as well as viruses whose susceptibility was altered during propagation. These criteria were consistent with statistical-based criteria for detecting outliers and will be useful in harmonizing NI assay data among surveillance laboratories worldwide and in establishing laboratory correlates of clinically relevant resistance.
format Online
Article
Text
id pubmed-4186475
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41864752014-10-29 Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria Okomo-Adhiambo, Margaret Nguyen, Ha T Abd Elal, Anwar Sleeman, Katrina Fry, Alicia M Gubareva, Larisa V Influenza Other Respir Viruses Original Articles BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC(50) values indicative of clinically relevant resistance and insufficient harmonization of NI testing methodologies among surveillance laboratories. In 2012, the WHO working group on influenza antiviral susceptibility (WHO-AVWG) developed criteria to facilitate consistent interpretation and reporting of NI assay data. METHODS: The WHO-AVWG classification criteria were applied in interpreting NI assay data for two FDA-licensed NAIs, oseltamivir and zanamivir, for viruses collected in the United States during the 2011–2012 winter season. RESULTS: All A (H1N1)pdm09 viruses (n = 449) exhibited normal inhibition by oseltamivir and zanamivir, with the exception of eight viruses (1·8%) with highly reduced inhibition by oseltamivir, which carried the H275Y marker of oseltamivir resistance. A (H3N2) viruses (n = 978) exhibited normal inhibition by both NAIs, except for one virus with highly reduced inhibition by zanamivir due to the cell culture-selected NA change, Q136K. Type B viruses (n = 343) exhibited normal inhibition by both drugs, except for an isolate with reduced inhibition by both NAIs that had the cell culture-selected A200T substitution. CONCLUSIONS: WHO-AVWG classification criteria allowed the detection of viruses carrying the established oseltamivir resistance marker, as well as viruses whose susceptibility was altered during propagation. These criteria were consistent with statistical-based criteria for detecting outliers and will be useful in harmonizing NI assay data among surveillance laboratories worldwide and in establishing laboratory correlates of clinically relevant resistance. Blackwell Publishing Ltd 2014-03 2013-12-02 /pmc/articles/PMC4186475/ /pubmed/24299049 http://dx.doi.org/10.1111/irv.12215 Text en © 2013 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Okomo-Adhiambo, Margaret
Nguyen, Ha T
Abd Elal, Anwar
Sleeman, Katrina
Fry, Alicia M
Gubareva, Larisa V
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
title Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
title_full Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
title_fullStr Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
title_full_unstemmed Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
title_short Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
title_sort drug susceptibility surveillance of influenza viruses circulating in the united states in 2011-2012: application of the who antiviral working group criteria
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186475/
https://www.ncbi.nlm.nih.gov/pubmed/24299049
http://dx.doi.org/10.1111/irv.12215
work_keys_str_mv AT okomoadhiambomargaret drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria
AT nguyenhat drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria
AT abdelalanwar drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria
AT sleemankatrina drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria
AT fryaliciam drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria
AT gubarevalarisav drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria